Pharmacogenomic Study to Predict Toxicity and Response in Colorectal Cancer Patients Treated With Oxaliplatin-based Chemotherapy
To investigate the impact of single nucleotide (SNP) polymorphism on the toxicity profile in
colorectal cancer patients treated with FOLFOX chemotherapy, 10 cc of blood will be drawn in
EDTA tube for extraction. DNA will be extracted from peripheral blood samples using DNA
isolation kit, and SNP polymorphisms will be evaluated.
Observational
Observational Model: Cohort, Time Perspective: Prospective
neuropathy
six months
Yes
Se Hoon Park, MD
Principal Investigator
Samsung Medical Center, Seoul, Korea
South Korea: Korea Food and Drug Administration (KFDA)
2008-05-052
NCT00977717
September 2008
April 2010
Name | Location |
---|